CARMAT is a medtech company that develops and manufactures bioprosthetic artificial hearts for the healthcare industry.
CARMAT is a medtech company that develops and manufactures bioprosthetic artificial hearts for the healthcare industry. The company is offering biocompatible, auto-regulated total artificial hearts, including right and left ventricles designed to be as close as possible to the human heart. It is designed for patients suffering from chronic terminal heart failure reaching class IV on the New York Heart Association classification; or acute terminal heart failure following a massive myocardial infarction.CARMAT’s aim is to offer a reliable new treatment and innovative therapeutic solution to heart failure patients, who are not eligible for a transplant and who have exhausted every drug-related possibility. It was launched in 2008 and is based in Vélizy-villacoublay.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Dec 19, 2022 | Post-IPO Equity | €15M | 1 | European Innovation Council | — | Detail |
Dec 19, 2022 | Grant | €2.50M | 1 | European Innovation Council | — | Detail |
Dec 18, 2018 | Post-IPO Debt | €30M | 1 | European Investment Bank | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
European Innovation Council | Yes | Post-IPO Equity |
European Investment Bank | Yes | Post-IPO Debt |